Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059474 | 0.88 | DUT (0.35) | DUT | |
| SCHEMBL4717834 | 0.82 | — | — | |
| SCHEMBL15115934 | 0.81 | DUT (0.31) | DUT | |
| SCHEMBL4714377 | 0.81 | BTN3A1 (0.33) | DUT | |
| SCHEMBL2870446 | 0.79 | DUT (0.33) | DUT | |
| SCHEMBL4074889 | 0.78 | — | — | |
| SCHEMBL23532351 | 0.76 | — | — | |
| SCHEMBL23573656 | 0.75 | TET2 (0.37) | DUT | |
| SCHEMBL10592319 | 0.74 | DUT (0.32) | DUT | |
| SCHEMBL13518253 | 0.74 | DUT (0.35) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059200-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-113166177-B | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-4413012-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | Studiengesellschaft Kohle gGmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023110394-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| EP-4198038-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | Studiengesellschaft Kohle mbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| EP-2834239-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | Astrazeneca AB (SE) | 2015-02-11 | — | — | EP | disclosed |
| US-8598161-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |
| US-20130131049-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-23 | — | — | US | disclosed |
| US-20130131049-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-23 | — | — | US | disclosed |
| US-20130131049-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-23 | — | — | US | disclosed |
| WO-2012162334-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059200-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | GGH, GEMIN4, GMNN | DUT 2312/4885 |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | BCL6B, BCL6, BTD | DUT 1848/4885 |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, SI | DUT 2790/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | DUT 1892/4885 |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | LCT, MGAM, SI | DUT 2790/4885 |
| US-20130131049-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DUT 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.